Immunomodulatory therapy for melanoma: ipilimumab and beyond
MK Callahan, MA Postow, JD Wolchok - Clinics in dermatology, 2013 - Elsevier
In 2011, the US Food and Drug Administration approved the first new therapy for melanoma
in more than a decade, ipilimumab (Yervoy). Ipilimumab is a novel antibody that blocks
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a regulatory molecule expressed on
activated T cells. Blockade of this important immune checkpoint can lead to durable tumor
regression, and phase III studies show an overall survival benefit for patients with advanced
melanoma. During the clinical development of ipilimumab, several unique features of this …
in more than a decade, ipilimumab (Yervoy). Ipilimumab is a novel antibody that blocks
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a regulatory molecule expressed on
activated T cells. Blockade of this important immune checkpoint can lead to durable tumor
regression, and phase III studies show an overall survival benefit for patients with advanced
melanoma. During the clinical development of ipilimumab, several unique features of this …